Article
Cardiac & Cardiovascular Systems
Lucas C. Godoy, Michael E. Farkouh, Peter C. Austin, Baiju R. Shah, Feng Qiu, Cynthia A. Jackevicius, Harindra C. Wijeysundera, Harlan M. Krumholz, Dennis T. Ko
Summary: Beta-blockers are associated with a small but significant reduction in cardiovascular events in patients with stable coronary artery disease. This effect is mainly driven by a reduction in myocardial infarction hospitalization.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Fabian Hoffmann, Patricia Fassbender, Wilhelm Zander, Lisa Ulbrich, Kathrin Kuhr, Christoph Adler, Marcel Halbach, Hannes Reuter
Summary: Patients with a history of hypertension have a higher adoption of guideline-recommended drug therapy after STEMI, which could contribute to better survival. Better tolerance of beta-blockers and RAS inhibitors in patients with a history of hypertension, rather than hypertension itself, likely explains the differences in prescription and dosing.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Peripheral Vascular Disease
Junxiong Lin, Qinghui Guo, Zhuoqiang Lu, Dajun Chai, Feng Peng, Jinxiu Lin
Summary: This retrospective study compared cardiovascular outcomes between initial beta-blocker + calcium channel blocker dual therapy (B + C) and other initial dual therapies in Chinese newly diagnosed hypertensive patients. After propensity score matching, patients receiving B + C had a significantly lower risk of major adverse cardiovascular events (MACE), non-fatal stroke, and non-fatal chronic heart failure (CHF) compared to patients receiving other initial dual therapies. The study suggests that B + C initial dual therapy may be more beneficial for Chinese newly diagnosed hypertensive patients in terms of cardiovascular outcomes.
JOURNAL OF CLINICAL HYPERTENSION
(2023)
Article
Biochemistry & Molecular Biology
Raffaele Maio, Edoardo Suraci, Benedetto Caroleo, Cristina Politi, Simona Gigliotti, Angela Sciacqua, Francesco Andreozzi, Francesco Perticone, Maria Perticone
Summary: The study suggests that endothelial dysfunction plays a significant role in the pathways leading to diabetes and cardiovascular events in hypertensive patients. Analysis using an illness-event model indicates that a decrease in forearm blood flow is associated with an increased risk of cardiovascular events and diabetes in these patients.
Article
Health Care Sciences & Services
Savannah Collett, Amanda Massmann, Natasha J. J. Petry, Joel Van Heukelom, April Schultz, Tadd Hellwig, Jordan F. F. Baye
Summary: This study aimed to evaluate adverse effects such as bradycardia, hypotension, and syncope in patients who are expected to have absent CYP2D6 enzyme activity due to drug-drug or drug-gene interactions. The study found that CYP2D6 poor metabolizers taking metoprolol had an increased risk of bradycardia. This study further supports the role of genetic testing in precision medicine.
JOURNAL OF PERSONALIZED MEDICINE
(2023)
Article
Medicine, General & Internal
Satoshi Washino, Yusuke Ugata, Kimitoshi Saito, Tomoaki Miyagawa
Summary: The study found that calcium channel blockers (CCBs) were associated with nocturia, while other AHTs and elevated blood pressure were not significantly associated.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Cardiac & Cardiovascular Systems
Daisuke Kanda, Takuro Takumi, Akihiro Tokushige, Yoshiyuki Ikeda, Mitsuru Ohishi
Summary: Diabetes mellitus (DM) and hypertension are risk factors for atherosclerosis, and renal dysfunction is a crucial risk factor for patients with coronary artery disease (CAD). This study aimed to investigate the effect of hypertension medications on renal function after percutaneous coronary intervention (PCI).
BMC CARDIOVASCULAR DISORDERS
(2023)
Article
Clinical Neurology
Amy E. Rumora, Kai Guo, Fadhl M. Alakwaa, Signe T. Andersen, Evan L. Reynolds, Marit E. Jorgensen, Daniel R. Witte, Hatice Tankisi, Morten Charles, Masha G. Savelieff, Brian C. Callaghan, Troels S. Jensen, Eva L. Feldman
Summary: The study suggests that diabetic polyneuropathy in type 2 diabetes is associated with novel alterations in plasma metabolites related to lipid metabolism. Findings also indicate changes in plasma lipid metabolites, including abundance, chain length, and saturation of free fatty acids in type 2 diabetes participants. Additionally, the presence of diabetic polyneuropathy impacts the abundance of complex plasma lipids, such as acylcarnitines and sphingolipids.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY
(2021)
Review
Cardiac & Cardiovascular Systems
Melanie J. Davies, Heinz Drexel, Francois R. Jornayvaz, Zoltan Pataky, Petar M. Seferovic, Christoph Wanner
Summary: Cardiovascular disease is the leading cause of mortality in patients with type 2 diabetes. Data from cardiovascular outcomes trials show that certain glucose-lowering medications, such as SGLT2 inhibitors and GLP-1 receptor agonists, have cardioprotective effects and can reduce cardiovascular events and mortality risk, as well as the risks of heart failure hospitalization, renal disease progression, and all-cause mortality. International guidelines now prioritize the use of these medications in the management of type 2 diabetes.
CARDIOVASCULAR DIABETOLOGY
(2022)
Letter
Gastroenterology & Hepatology
William Shanahan, Maeve Clarke, Eimear Carolan, John D. Ryan
Summary: This article is linked to the paper by Gillespie et al. To view this article, visit the link.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Peripheral Vascular Disease
Boyang Xiang, Yujia Zhou, Xiaoguang Wu, Xiang Zhou
Summary: This study aimed to investigate the long-term benefits of physical activity for individuals with hypertension. The findings suggested that moderate-intensity physical activity was associated with a lower risk of cardiovascular events and all-cause mortality. However, higher intensities of physical activity did not provide additional benefits.
Article
Medicine, General & Internal
Natalie K. Binder, Teresa M. MacDonald, Sally A. Beard, Natasha de Alwis, Stephen Tong, Tu'uhevaha J. Kaitu'u-Lino, Natalie J. Hannan
Summary: Research suggests that beta-blockers can promote the expression of pro-angiogenic factors, reduce secretion of anti-angiogenic factors, decrease inflammation markers, alleviate endothelial dysfunction, and contribute to cytoprotective effects in endothelial cells.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Immunology
Sushma Devi, Samrat Chauhan, Ashi Mannan, Thakur Gurjeet Singh
Summary: Inflammation is a reaction to stimuli and linked to chronic diseases. Inflammatory markers in the blood are risk factors for cardiovascular diseases, while eugenol, found in essential oils, has anti-inflammatory properties and may reduce the risk of cardiovascular diseases.
INFLAMMOPHARMACOLOGY
(2023)
Article
Clinical Neurology
Peter Trillenberg, Alexander Katalinic, Julia Thern, Tobias Graf
Summary: This study analyzed the risk of adverse reactions of different cardiovascular drugs and related mechanism drugs on patients with myasthenia from the World Health Organization pharmacovigilance database. The results indicate that angiotensin receptor antagonists, angiotensin-converting enzyme inhibitors, and diuretics are safe in antihypertensive therapy, while alpha receptor-blocking drugs may carry a risk of worsening myasthenia. These findings suggest the need for further research and confirmation.
EUROPEAN JOURNAL OF NEUROLOGY
(2021)
Article
Oncology
Magdalena Zaborowska-Szmit, Sebastian Szmit, Marta Olszyna-Serementa, Pawel Badurak, Katarzyna Zajda, Anna Janowicz-Zebrowska, Aleksandra Piorek, Magdalena Knetki-Wroblewska, Piotr Jaskiewicz, Adam Pluzanski, Maciej Krzakowski, Dariusz M. Kowalski
Summary: Concurrent platinum-based chemoradiotherapy (CRT) followed by maintenance treatment with the PD-L1 inhibitor durvalumab is the most effective therapy in unresectable stage III non-small-cell lung cancer (NSCLC). However, severe toxicity may lead to unsatisfactory outcomes. Sequential CRT may be a better choice for patients with cardiovascular diseases (CVD) to avoid adverse events and maintain effectiveness. Beta-blockers and statins can significantly reduce all-cause mortality in these patients, and may serve as a prevention strategy in NSCLC patients undergoing CRT.